Frederic J Kaye, M.D.
Professor
Department:
Molecular Genetics & Microbiology
Business Phone:
(352) 273-7832
Business Email:
fkaye@ufl.edu
About Frederic J Kaye
Dr. Kaye is a professor of medicine, medical director of the thoracic oncology program and director of the lung cancer center within the division of hematology and oncology. He is a clinical and basic science investigator with a focus on thoracic malignancies. Dr. Kay is an elected member of the American Society for Clinical Investigation, the Alpha Omega Alpha medical honor society, and serves as Associate Editor of the Journal of the National Cancer Institute.
Teaching Profile
Courses Taught
2019-2023
GMS6691 Special Topics in Cell Biology and Anatomy
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2018
MDC7203 Senior Medicine Clerk
2018
MDC7200 Medicine Clerkship
2021-2024
GMS6065 Fundamentals of Cancer Biology
Board Certifications
-
HematologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
-
OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology
- Hematology and Oncology
Areas of Interest
- Cancer – resources
- Head and Neck Cancer
- Lung Cancer
- Lung cancer – small cell
- Lung disease – resources
- Malignant mesothelioma
- Non-small cell lung cancer
- Oral cancer
- Salivary gland tumors
- Throat or larynx cancer
- Thyroid cancer
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-8565-1854
Publications
2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
Journal for immunotherapy of cancer.
12(2)
[DOI] 10.1136/jitc-2023-007883.
[PMID] 38316517.
2024
Patient-Provider Discussion About Lung Cancer Screening by Race and Ethnicity: Implications for Equitable Uptake of Lung Cancer Screening.
Clinical lung cancer.
25(1):39-49
[DOI] 10.1016/j.cllc.2023.08.013.
[PMID] 37673782.
2024
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Cells.
13(6)
[DOI] 10.3390/cells13060528.
[PMID] 38534371.
2024
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.27.582353.
[PMID] 38464204.
2023
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Cell Death Discovery.
9(1)
[DOI] 10.1038/s41420-022-01296-8.
[PMID] 36588105.
2023
Disparities Contributing to Late-Stage Diagnosis of Lung, Colorectal, Breast, and Cervical Cancers: Rural and Urban Poverty in Florida.
Cancers.
15(21)
[DOI] 10.3390/cancers15215226.
[PMID] 37958400.
2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival.
JCI insight.
8(10)
[DOI] 10.1172/jci.insight.158798.
[PMID] 37097751.
2023
PROTAC therapy as a new targeted therapy for lung cancer.
Molecular therapy : the journal of the American Society of Gene Therapy.
31(3):647-656
[DOI] 10.1016/j.ymthe.2022.11.011.
[PMID] 36415148.
2023
TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background
Oncogene.
42(23):1926-1939
[DOI] 10.1038/s41388-023-02694-7.
[PMID] 37106126.
2022
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Journal of hematology & oncology.
15(1)
[DOI] 10.1186/s13045-022-01241-3.
[PMID] 35260176.
2022
Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up.
Oral oncology.
128
[DOI] 10.1016/j.oraloncology.2022.105854.
[PMID] 35447565.
2022
Personalised Lung Cancer Screening (PLuS) study to assess the importance of coexisting chronic conditions to clinical practice and policy: protocol for a multicentre observational study.
BMJ open.
12(6)
[DOI] 10.1136/bmjopen-2022-064142.
[PMID] 35732383.
2022
Reducing Chemotherapy-Induced DNA Damage via nAChR-Mediated Redox Reprograming-A New Mechanism for SCLC Chemoresistance Boosted by Nicotine.
Cancers.
14(9)
[DOI] 10.3390/cancers14092272.
[PMID] 35565402.
2022
Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival.
JCI insight.
7(19)
[DOI] 10.1172/jci.insight.147417.
[PMID] 36048542.
2021
Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation.
eLife.
10
[DOI] 10.7554/eLife.66095.
[PMID] 34142658.
2021
Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma.
Signal transduction and targeted therapy.
6(1)
[DOI] 10.1038/s41392-020-00388-0.
[PMID] 33473104.
2021
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma.
JCI insight.
6(7)
[DOI] 10.1172/jci.insight.139497.
[PMID] 33830080.
2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Nature Medicine.
27(8):1410-1418
[DOI] 10.1038/s41591-021-01462-y.
[PMID] 34385708.
2020
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
26(2):439-449
[DOI] 10.1158/1078-0432.CCR-19-1667.
[PMID] 31548343.
2020
Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
The oncologist.
25(9):810-817
[DOI] 10.1634/theoncologist.2019-0877.
[PMID] 32372416.
2019
Adaptive Transcriptional Responses by CRTC Coactivators in Cancer.
Trends in cancer.
5(2):111-127
[DOI] 10.1016/j.trecan.2018.12.002.
[PMID] 30755304.
2019
Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.
Head & neck.
41(4):E55-E58
[DOI] 10.1002/hed.25528.
[PMID] 30614125.
2019
MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Oral oncology.
98:147-155
[DOI] 10.1016/j.oraloncology.2019.09.005.
[PMID] 31606723.
2019
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
The Journal of clinical investigation.
129(6):2279-2292
[DOI] 10.1172/JCI121323.
[PMID] 31033480.
2019
Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
Journal of the National Cancer Institute.
111(7):664-674
[DOI] 10.1093/jnci/djy166.
[PMID] 30423141.
2018
CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.
Oncotarget.
9(100):37352-37366
[DOI] 10.18632/oncotarget.26424.
[PMID] 30647837.
2018
CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells.
Oncogene.
37(14):1885-1895
[DOI] 10.1038/s41388-017-0104-0.
[PMID] 29353885.
2018
Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose.
Cancer investigation.
36(5):289-295
[DOI] 10.1080/07357907.2018.1479415.
[PMID] 30040495.
2018
The Prevalence of Rhesus-Negative Blood Group Among Patient With Small Cell Lung Cancer and Analysis of Its Effect on Overall Survival.
Frontiers in oncology.
8
[DOI] 10.3389/fonc.2018.00358.
[PMID] 30250826.
2017
Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.
Human gene therapy methods.
28(1):49-59
[DOI] 10.1089/hgtb.2016.089.
[PMID] 28125909.
2017
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Clinical lung cancer.
18(1):68-76.e2
[DOI] 10.1016/j.cllc.2016.09.002.
[PMID] 28341109.
2017
Response.
Journal of the National Cancer Institute.
109(1)
[PMID] 27671685.
2017
Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.
Cancer genetics.
216-217:20-28
[DOI] 10.1016/j.cancergen.2017.05.003.
[PMID] 29025592.
2016
A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
11(6):838-49
[DOI] 10.1016/j.jtho.2016.02.009.
[PMID] 26917230.
2016
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
The Journal of clinical investigation.
126(6):2267-79
[DOI] 10.1172/JCI85250.
[PMID] 27140397.
2016
MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.
American journal of cancer research.
6(9):1996-2009
[PMID] 27725905.
2016
Silencing Receptor Epha2 Enhanced Sensitivity to Lipoplatin (Tm) in Lung Tumor and Mpm Cells
Cancer Investigation.
34(7):293-304
[DOI] 10.1080/07357907.2016.1201678.
2016
Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery.
273(10):3293-7
[DOI] 10.1007/s00405-016-3899-3.
[PMID] 26796877.
2015
Cisplatin Loaded Albumin Mesospheres for Lung Cancer Treatment
American Journal of Cancer Research.
5(2):603-615
2015
Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.
Journal of the National Cancer Institute.
107(1)
[DOI] 10.1093/jnci/dju378.
[PMID] 25475564.
2015
Re: a cancer theory kerfuffle can lead to new lines of research.
Journal of the National Cancer Institute.
107(5)
[DOI] 10.1093/jnci/djv060.
[PMID] 25766401.
2015
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.
Journal of the National Cancer Institute.
107(1)
[DOI] 10.1093/jnci/dju358.
[PMID] 25465874.
2015
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Journal of the National Cancer Institute.
107(8)
[DOI] 10.1093/jnci/djv123.
[PMID] 25971297.
2014
A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.
Oncotarget.
5(24):12528-42
[PMID] 25587024.
2014
Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.
Oncogene.
33(29):3869-77
[DOI] 10.1038/onc.2013.348.
[PMID] 23975434.
2014
Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
International journal of cancer.
135(1):128-37
[DOI] 10.1002/ijc.28675.
[PMID] 24347111.
2014
CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.
Proceedings of the National Academy of Sciences of the United States of America.
111(32):E3260-8
[DOI] 10.1073/pnas.1319176111.
[PMID] 25071166.
2014
Deregulated Ts Promotes Tumor Progression in Diverse Hematopoietic and Mesenchymal Cell Lineages
Cancer Research.
74(19, S):2042-2042
[DOI] 10.1158/1538-7445.AM2014-2042.
2014
Recurrent dermatophytosis (Majocchi granuloma) associated with chemotherapy-induced neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
32(27):e92-4
[PMID] 24470005.
2013
Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma.
Oral oncology.
49(11):1059-66
[DOI] 10.1016/j.oraloncology.2013.08.004.
[PMID] 24035723.
2013
Directed Evolution of Aav Capsid for Targeted Cancer Therapy
Molecular Therapy.
21
2013
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Cancer genetics.
206(5):191-205
[DOI] 10.1016/j.cancergen.2013.04.006.
[PMID] 23830731.
2013
The 3rd Salivary Gland Tumor Workshop meeting report.
Head & neck.
35(8):1057-60
[DOI] 10.1002/hed.23374.
[PMID] 23677839.
2012
Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion.
Oncogene.
31(4):469-79
[DOI] 10.1038/onc.2011.247.
[PMID] 21706049.
2012
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.
Molecular cancer therapeutics.
11(2):370-82
[DOI] 10.1158/1535-7163.MCT-11-0458.
[PMID] 22203734.
2012
Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
BMC cancer.
12
[DOI] 10.1186/1471-2407-12-309.
[PMID] 22824143.
2011
CRTC1 expression during normal and abnormal salivary gland development supports a precursor cell origin for mucoepidermoid cancer.
Gene expression patterns : GEP.
11(1-2):57-63
[DOI] 10.1016/j.gep.2010.09.003.
[PMID] 20837164.
2011
Erlotinib or gefitinib for non-small-cell lung cancer.
The New England journal of medicine.
364(24)
[DOI] 10.1056/NEJMc1103918.
[PMID] 21675909.
2011
Novel Ampk/ Crtc Signaling Pathway in Metabolism and Lung Cancer
International Journal of Molecular Medicine.
28
2011
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
6(6):1142-3
[DOI] 10.1097/JTO.0b013e318217b684.
[PMID] 21623280.
2010
Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer.
Oncogene.
29(11):1672-80
[DOI] 10.1038/onc.2009.453.
[PMID] 20010869.
2010
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
International journal of oncology.
37(4):963-71
[PMID] 20811718.
2010
Lkb1 Regulates a Novel Crtc1: Creb: Nr4A2 Pathway in Lung Cancer
Journal of Thoracic Oncology.
5:S242-S243
2010
The landscape of somatic copy-number alteration across human cancers.
Nature.
463(7283):899-905
[DOI] 10.1038/nature08822.
[PMID] 20164920.
2010
Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions.
Genes, chromosomes & cancer.
49(1):59-69
[DOI] 10.1002/gcc.20719.
[PMID] 19827123.
2009
Meeting report–the NIDCR 2(nd) Salivary Gland Tumor Meeting, November 2008.
Head & neck.
31(12):1542-3
[DOI] 10.1002/hed.21307.
[PMID] 19890918.
2009
Mutation-associated fusion cancer genes in solid tumors.
Molecular cancer therapeutics.
8(6):1399-408
[DOI] 10.1158/1535-7163.MCT-09-0135.
[PMID] 19509239.
2008
CRTC1/MAML2 fusion transcript in Warthin’s tumor and mucoepidermoid carcinoma: evidence for a common genetic association.
Genes, chromosomes & cancer.
47(4):309-14
[DOI] 10.1002/gcc.20534.
[PMID] 18181164.
2008
Defining a candidate lung cancer gene.
Journal of the National Cancer Institute.
100(22):1564-5
[DOI] 10.1093/jnci/djn381.
[PMID] 19001597.
2008
Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.
Cell cycle (Georgetown, Tex.).
7(15):2384-91
[PMID] 18677112.
2007
CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin’s tumors: implications for histogenesis and biologic behavior.
Genes, chromosomes & cancer.
46(7):708-15
[PMID] 17437281.
2007
Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.
Oncogene.
26(33):4817-24
[PMID] 17297449.
2006
Emerging biology of malignant salivary gland tumors offers new insights into the classification and treatment of mucoepidermoid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
12(13):3878-81
[PMID] 16818681.
2006
Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.
Oncogene.
25(45):6128-32
[PMID] 16652146.
2005
A curious link between epidermal growth factor receptor amplification and survival: effect of “allele dilution” on gefitinib sensitivity?
Journal of the National Cancer Institute.
97(9):621-3
[PMID] 15870427.
2005
Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes.
Cancer research.
65(16):7137-44
[PMID] 16103063.
2004
A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin’s tumor of salivary glands.
The Journal of molecular diagnostics : JMD.
6(3):205-10
[PMID] 15269296.
2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science (New York, N.Y.).
304(5676):1497-500
[PMID] 15118125.
2004
Evolutionary conservation of a 2-kb intronic sequence flanking a tissue-specific alternative exon in the PTBP2 gene.
Genomics.
83(1):76-84
[PMID] 14667811.
2004
For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors.
Journal of the National Cancer Institute.
96(5):342-3
[PMID] 14996847.
2004
Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas.
Cancer genetics and cytogenetics.
152(1):15-22
[PMID] 15193437.
2004
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.
Cancer cell.
5(4):341-51
[PMID] 15093541.
2003
New leads suggest a clinically relevant genotype-phenotype relationship for the p53 gene.
Journal of the National Cancer Institute.
95(13):926-7
[PMID] 12837819.
2003
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells.
Cancer chemotherapy and pharmacology.
51(3):202-8
[PMID] 12655437.
2003
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway.
Nature genetics.
33(2):208-13
[PMID] 12539049.
2001
Molecular biology of lung cancer.
Lung cancer (Amsterdam, Netherlands).
34 Suppl 2:S35-41
[PMID] 11720739.
2001
Publishing negative data: beta-tubulin mutations in lung cancer.
Journal of the National Cancer Institute.
93(24):1832-3
[PMID] 11752001.
2001
Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.
Journal of the National Cancer Institute.
93(6):415-7
[PMID] 11259459.
2000
A family of ubiquitin-like proteins binds the ATPase domain of Hsp70-like Stch.
FEBS letters.
467(2-3):348-55
[PMID] 10675567.
2000
Assignment of ubiquilin2 (UBQLN2) to human chromosome xp11. 23–>p11.1 by GeneBridge radiation hybrids.
Cytogenetics and cell genetics.
89(1-2):116-7
[PMID] 10894951.
2000
Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt’s lymphoma.
Molecular and cellular biology.
20(14):5276-84
[PMID] 10866684.
2000
Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells.
The Biochemical journal.
345 Pt 3(Pt 3):535-41
[PMID] 10642512.
2000
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene.
19(40):4632-9
[PMID] 11030152.
1999
Closing in on another renal cancer suppressor locus near chromosome 3p14.
Journal of the National Cancer Institute.
91(18):1528-9
[PMID] 10491421.
1999
Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families.
American journal of human genetics.
65(4):1040-6
[PMID] 10486322.
1999
The 100-kDa proteolytic fragment of RB is retained predominantly within the nuclear compartment of apoptotic cells.
Molecular cell biology research communications : MCBRC.
1(3):216-20
[PMID] 10425229.
1999
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(12):4279-86
[PMID] 10632371.
1998
Protein expression and functional analysis of the FHIT gene in human tumor cells.
Journal of the National Cancer Institute.
90(6):426-32
[PMID] 9521166.
1998
RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer.
Oncogene.
17(12):1625-8
[PMID] 9794240.
1998
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth.
Genes & development.
12(1):95-106
[PMID] 9420334.
1998
The retinoblastoma-like protein family: still in the shadow of the RB gene?
Journal of the National Cancer Institute.
90(19):1418-9
[PMID] 9776402.
1997
A ‘core ATPase’, Hsp70-like structure is conserved in human, rat, and C. elegans STCH proteins.
Gene.
199(1-2):287-92
[PMID] 9358068.
1997
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding.
Oncogene.
14(10):1243-8
[PMID] 9121775.
1997
Can p53 status resolve paradoxes between human and non-human retinoblastoma models?
Journal of the National Cancer Institute.
89(20):1476-7
[PMID] 9337339.
1997
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
Proceedings of the National Academy of Sciences of the United States of America.
94(22):12036-40
[PMID] 9342358.
1996
Clinical significance of the FV:Q506 mutation in unselected oncology patients.
The American journal of medicine.
101(4):406-12
[PMID] 8873512.
1996
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
Proceedings of the National Academy of Sciences of the United States of America.
93(9):4350-4
[PMID] 8633069.
1995
CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2’deoxycytidine.
Oncogene.
11(6):1211-6
[PMID] 7566983.
1995
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
International journal of cancer.
63(2):226-30
[PMID] 7591209.
1995
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
Journal of the National Cancer Institute.
87(24):1870-5
[PMID] 7494231.
1995
Localization of STCH to human chromosome 21q11.1.
Genomics.
30(3):627-8
[PMID] 8825657.
1995
Molecular genetic characterization of neuroendocrine lung cancer cell lines.
Anticancer research.
15(2):225-32
[PMID] 7762988.
1995
The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro.
Molecular and cellular biology.
15(9):5188-95
[PMID] 7651436.
1994
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
Oncogene.
9(11):3375-8
[PMID] 7936665.
1994
Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein.
Molecular and cellular biology.
14(11):7256-64
[PMID] 7935440.
1994
Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors.
Oncogene.
9(5):1321-6
[PMID] 8152792.
1994
Stch encodes the ‘ATPase core’ of a microsomal stress 70 protein.
The EMBO journal.
13(5):1216-25
[PMID] 8131751.
1993
Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites.
Oncogene.
8(4):949-57
[PMID] 8455946.
1993
RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
4(8):629-35
[PMID] 8398904.
1992
Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers.
International journal of cancer.
52(5):718-25
[PMID] 1330929.
1992
Functional analysis at the Cys706 residue of the retinoblastoma protein.
The Journal of biological chemistry.
267(36):25998-6003
[PMID] 1334491.
1992
Oncogenes in human lung cancer.
Cancer treatment and research.
63:61-85
[PMID] 1363367.
1990
A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.
Proceedings of the National Academy of Sciences of the United States of America.
87(17):6922-6
[PMID] 2168563.
1990
Expression in lung cancer of a transcribed sequence at the DNF15S2 locus at chromosome 3P21.
Anticancer research.
10(1):23-7
[PMID] 2159253.
1990
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.
Proceedings of the National Academy of Sciences of the United States of America.
87(7):2775-9
[PMID] 2181449.
1990
Recessive oncogenes in lung cancer.
The American review of respiratory disease.
142(6 Pt 2):S44-7
[PMID] 2174662.
1989
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.
The New England journal of medicine.
321(26):1784-90
[PMID] 2594037.
1989
Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer.
International journal of cancer. Supplement = Journal international du cancer. Supplement.
4:32-4
[PMID] 2530182.
1988
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.
Science (New York, N.Y.).
241(4863):353-7
[PMID] 2838909.
1987
Human creatine kinase-B complementary DNA. Nucleotide sequence, gene expression in lung cancer, and chromosomal assignment to two distinct loci.
The Journal of clinical investigation.
79(5):1412-20
[PMID] 2883200.
Grants
Apr 2023
ACTIVE
Elucidating and targeting INSL4 signaling in lung cancer
Role: Project Manager
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Jul 2022
ACTIVE
Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
Role: Principal Investigator
Funding: UNIV OF TEXAS HLTH SCI CTR SAN ANTONIO
via NATL INST OF HLTH NCI
Feb 2022
ACTIVE
The Role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLC
Role: Co-Project Director/Principal Investigator
Funding: UNIV OF TEXAS HLTH SCI CTR SAN ANTONIO
via NATL INST OF HLTH NCI
Jul 2021
– Dec 2021
The Role of Lipid Metabolism in Anti-tumor Immunity in Lung Cancer
Role: Co-Investigator
Funding: AMER LUNG ASSO
Apr 2021
– Mar 2024
Optimizing the Population Representativeness of Older Adults in Cancer Trials
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Aug 2020
ACTIVE
Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland
Role: Project Manager
Funding: NATL INST OF HLTH NIDCR
Jul 2020
– Dec 2021
Protein kinase signaling in cisplatin-resistant ASCL1-high SCLC
Role: Other
Funding: US ARMY MED RES ACQUISITION
Jun 2020
– Nov 2021
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via GLAXO SMITHKLINE
Feb 2020
– Oct 2023
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
Role: Principal Investigator
Funding: IQVIA Holdings
via MERSANA THERAPEUTICS
Feb 2020
– Dec 2021
The role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLC
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Dec 2019
– Dec 2021
Targeting MAST1-BCL2 signaling in small cell lung cancer
Role: Co-Project Director/Principal Investigator
Funding: LUNG CANCER RESEARCH FOUNDATION
Sep 2019
– Mar 2023
Testing novel drug combination for pancreatic cancer
Role: Co-Project Director/Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jul 2019
ACTIVE
LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jul 2019
– Jun 2020
Targeting NFIB-MAST1 signaling in cisplatin-resistant small cell lung cancer
Role: Co-Investigator
Funding: PARDEE FOU, ELSA U
Feb 2019
– Feb 2024
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNa
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Feb 2019
ACTIVE
Aberrant CRTC activation as a unique vulnerability of lung cancer with LKB1 inactivation
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Nov 2018
– Nov 2023
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as
Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Role: Principal Investigator
Funding: DRUGDEV INC
via Merck Sharp & Dohme
Sep 2018
– Feb 2019
ET-CTN with Phase 2 Emphasis
Role: Other
Funding: UNIV OF PITTSBURGH
via NATL INST OF HLTH NCI
Aug 2018
– May 2020
Tumor Infiltrating lymphocyte adoptive T cell therapy for NSCLC
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via AMER ASSO FOR CANCER RESEARCH
Aug 2018
– May 2019
A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Non-Small Cell Lung Cancer
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
Jun 2018
– Mar 2023
Good manufacturing Practice (GMP) production to allow Phase 1 clinical trial testing intralesional delivery of myxomavirus to patients with advanced small cell lung cancer
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jan 2018
– Dec 2023
SMK-1, a novel, conserved nuclear activator of DAF-16/FOXO tumor suppressor
Role: Faculty
Funding: AMERICAN CANCER SOCIETY
Jul 2017
– Jun 2018
4th International Conference on Malignant Salivary Gland Tumors
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDCR
Jan 2017
– Jan 2019
RANDOMIZED, DOUBLE BLINDED PHASE III TRIAL OF CISPLATIN AND ETOPOSIDE PLUS THORACIC RADIATION THERAPY FOLLOWED BY NIVOLUMAB/PLACEBO FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Role: Principal Investigator
Funding: RADIATION THERAPY ONCOLOGY GROUP FOU
Oct 2016
– Oct 2021
An open-label Phase I dose-escalation study to evaluate the safety, tolerability,
maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a
antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to
express C4.4a
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Sep 2016
– Sep 2021
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Aug 2016
– Aug 2021
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Role: Principal Investigator
Funding: STEMCENTRX INC
Jun 2016
– Mar 2022
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Jan 2016
– Dec 2021
ufhcc-ioa cancer-aging collaborative team grants
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Sep 2015
– Sep 2018
Epha2 -/- NK Cell Therapy against Malignant Pleural Mesothelioma
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
May 2015
– May 2019
First-of-its-kind study of oncolytic virotherapy for Small Cell Lung Cancer (SCLC) using mouse models and human ex-vivo intralesional analyses
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Apr 2015
– Mar 2018
A novel noncoding RNA and human lung cancers with inactivated LKB1 signaling
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Mar 2015
– Mar 2018
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via CLOVIS ONCOLOGY INC
Mar 2015
– Mar 2018
TIGER-3: A PHASE 3, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY OF ORAL ROCILETINIB (CO-1686) MONOTHERAPY VERSUS SINGLE…
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via CLOVIS ONCOLOGY INC
Jan 2015
– Jun 2023
Editorship for "Journal of the National Cancer Institute"
Role: Principal Investigator
Funding: OXFORD UNIVERSITY PRESS
Dec 2014
– Dec 2019
A PHASE III, OPEN LABEL, RANDOMIZED STUDY OF AZD9291 VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR PATIENTS WITH …
Role: Principal Investigator
Funding: CLINICAL FINANCIAL SERVICES
via ASTRAZENECA
Dec 2014
– Dec 2017
A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth
Role: Principal Investigator
Funding: CLINICAL FINANCIAL SERVICES
via ASTRAZENECA
Aug 2014
– May 2020
Signaling and targeting of CRTC1-MAML2 fusion oncoprotein in salivary gland tumor
Role: Project Manager
Funding: NATL INST OF HLTH
Oct 2013
– Oct 2016
An Open-label, Randomized Phase IIb/III Active Control Study of Second-line HyperAcute?-Lung (tergenpumatucel-L) Immunotherapy versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer
Role: Principal Investigator
Funding: NEW LINK GENETICS
Oct 2013
– Oct 2019
AN OPEN-LABEL, RANDOMIZED PHASE IIB/III ACTIVE CONTROL STUDYOF SECOND-LINE HYPERACUTE?-LUNG (TERGENPUMATUCEL-L) ….
Role: Principal Investigator
Funding: NEW LINK GENETICS
Aug 2011
– Jul 2016
Small Cell Lung Cancer, sponsor code 7275
Role: Principal Investigator
Funding: UF FOUNDATION
Education
Fellowship – Oncology
1987
·
National Cancer Institute
Fellowship – Hematology
1984
·
Mount Sinai Hospital
Residency – Internal Medicine
1982
·
Mount Sinai Hospital
Internship – Internal Medicine
1980
·
Mount Sinai Hospital
Medical Degree
1979
·
University of Maryland
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- fkaye@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
2033 MOWRY RD
GAINESVILLE FL 32610